243 related articles for article (PubMed ID: 26879560)
1. Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).
Hauben M; Aronson JK; Ferner RE
Drug Saf; 2016 May; 39(5):421-32. PubMed ID: 26879560
[TBL] [Abstract][Full Text] [Related]
2. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
[TBL] [Abstract][Full Text] [Related]
3. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.
Coloma PM; Avillach P; Salvo F; Schuemie MJ; Ferrajolo C; Pariente A; Fourrier-Réglat A; Molokhia M; Patadia V; van der Lei J; Sturkenboom M; Trifirò G
Drug Saf; 2013 Jan; 36(1):13-23. PubMed ID: 23315292
[TBL] [Abstract][Full Text] [Related]
4. A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.
Pham M; Cheng F; Ramachandran K
Drug Saf; 2019 Jun; 42(6):743-750. PubMed ID: 30762164
[TBL] [Abstract][Full Text] [Related]
5. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.
Schuemie MJ; Gini R; Coloma PM; Straatman H; Herings RM; Pedersen L; Innocenti F; Mazzaglia G; Picelli G; van der Lei J; Sturkenboom MC
Drug Saf; 2013 Oct; 36 Suppl 1():S159-69. PubMed ID: 24166232
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.
Zhou X; Murugesan S; Bhullar H; Liu Q; Cai B; Wentworth C; Bate A
Drug Saf; 2013 Feb; 36(2):119-34. PubMed ID: 23329543
[TBL] [Abstract][Full Text] [Related]
7. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
Clin Pharmacol Ther; 2013 Jun; 93(6):539-46. PubMed ID: 23571771
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug effect detection.
Lian Duan L; Khoshneshin M; Street WN; Liu M
IEEE J Biomed Health Inform; 2013 Mar; 17(2):305-11. PubMed ID: 24235108
[TBL] [Abstract][Full Text] [Related]
9. Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions.
Kontsioti E; Maskell S; Pirmohamed M
Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):832-844. PubMed ID: 36916014
[TBL] [Abstract][Full Text] [Related]
10. Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases.
Whalen E; Hauben M; Bate A
Drug Saf; 2018 Jun; 41(6):565-577. PubMed ID: 29468602
[TBL] [Abstract][Full Text] [Related]
11. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Mapping Austrian Health Claims Data to the OMOP Common Data Model.
Haberson A; Rinner C; Schöberl A; Gall W
J Med Syst; 2019 Sep; 43(10):314. PubMed ID: 31494719
[TBL] [Abstract][Full Text] [Related]
13. Bayesian model selection in logistic regression for the detection of adverse drug reactions.
Marbac M; Tubert-Bitter P; Sedki M
Biom J; 2016 Nov; 58(6):1376-1389. PubMed ID: 27225325
[TBL] [Abstract][Full Text] [Related]
14. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
[TBL] [Abstract][Full Text] [Related]
15. 3D pharmacophoric similarity improves multi adverse drug event identification in pharmacovigilance.
Vilar S; Tatonetti NP; Hripcsak G
Sci Rep; 2015 Mar; 5():8809. PubMed ID: 25744369
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance and Clinical Environment: Utilizing OMOP-CDM and OHDSI Software Stack to Integrate EHR Data.
Dimitriadis VK; Gavriilidis GI; Natsiavas P
Stud Health Technol Inform; 2021 May; 281():555-559. PubMed ID: 34042637
[TBL] [Abstract][Full Text] [Related]
17. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
[TBL] [Abstract][Full Text] [Related]
18. Patient Cohort Identification on Time Series Data Using the OMOP Common Data Model.
Maier C; Kapsner LA; Mate S; Prokosch HU; Kraus S
Appl Clin Inform; 2021 Jan; 12(1):57-64. PubMed ID: 33506478
[TBL] [Abstract][Full Text] [Related]
19. Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases.
Biedermann P; Ong R; Davydov A; Orlova A; Solovyev P; Sun H; Wetherill G; Brand M; Didden EM
BMC Med Res Methodol; 2021 Nov; 21(1):238. PubMed ID: 34727871
[TBL] [Abstract][Full Text] [Related]
20. A supervised adverse drug reaction signalling framework imitating Bradford Hill's causality considerations.
Reps JM; Garibaldi JM; Aickelin U; Gibson JE; Hubbard RB
J Biomed Inform; 2015 Aug; 56():356-68. PubMed ID: 26116429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
